Crohn’s disease in a patient with multiple sclerosis

Journal of Clinical Gastroenterology

Volumn 13, Issue 3, 1991, Pages 331-334

  Kitchin, Llewellyn I ^a   Knobler, Robert L ^a   Friedman, Lawrence S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Crohn s disease; Inflammatory bowel disease; Multiple sclerosis; Ulcerative colitis

Indexed keywords

CORTICOTROPIN; IMMUNOLOGIC FACTOR; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; FAMILIAL DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CASE REPORT; COLITIS; CROHN DISEASE; FEMALE; HUMAN; MIDDLE AGE; MULTIPLE SCLEROSIS;

EID: 0025816434     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/00004836-199106000-00017     Document Type: Article

References (17)

1. Hinds JP, Wald A. Colonic and anorectal dysfunction associated with multiple sclerosis. Am J Gastroenterol 1989; 84: 587-95.
2. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis: a population survey. Gastroenterology 1990; 98: 1538-42.
3. Weber J, Grise P, Roquebert M, et al. Radiopaque markers transit and anorectal manometry in 16 patients with multiple sclerosis and urinary bladder dysfunction. Dis Colon Rectum 1987; 30: 95-100.
4. Rang EH, Brooke BN, Hermon-Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet 1982; 2: 555.
5. Minuk GY, Lewkonia RM. Possible familial association of multiple sclerosis and inflammatory bowel disease. N Engl J Med 1986; 314: 586.
6. Sadovnick AD, Paty DW, Yannakoulias G. Concurrence of multiple sclerosis and inflammatory bowel disease. N Engl J Med 1989; 321: 762-3.
7. Weiner HL, Hafler DA. Immunotherapy of multiple sclerosis. Ann Neural 1988; 23: 211-22.
8. Elson CO. The immunology of inflammatory bowel disease. In: Kirshner JB, Shorter RG, eds. Inflammatory bowel disease. Philadelphia: Lea & Febiger, 1988; 97-164.
9. Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990; 112: 50-60.
10. Knobler RL, Rodriguez M, Lampert PW, Oldstone MB. Virologic models of chronic relapsing demyelinating disease. Acta Neuropathol [Suppl] 1983; 9: 31-9.
11. Holmes KV, Williams RK, Stephensen CB, et al. Coronavirus receptors. In: Compans RW, Helenius A, Oldstone MBA. eds. Cell biology of virus entry, replication, and pathogenesis. New York: Liss, 1989: 85-95.
12. Melvold RW, Jokinen DM, Knobler RL, Lipton HC. Variations in genetic control of susceptibility to Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease: differences between susceptible SJL/J and resistant BALB/c strain map near the T cell beta-chain constant gene on chromosome 6. J Immunol 1987; 138: 1429-33.
13. Raine CS, Traugott U. Experimental autoimmune demyelination: chronic relapsing models and their therapeutic implications for multiple sclerosis. Ann NY Acad Sci 1984; 436: 33-51.
14. Prosiegel M, Neu I, Mallinger J, et al. Suppression of experimental autoimmune encephalomyelitis by dual cyclooxygenase and 5-lipoxygenase inhibition. Acta Neural Scand 1989; 79: 223-6.
15. Prosiegal M, Neu I, Ruhenstroth-Baur G, et al. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine. N Engl J Med 1989; 321: 545-6.
16. Gold R, Kappos L, Becker T. Development of multiple sclerosis in patient on long-term sulfasalazine. Lancet 1990; 1: 409-10.
17. Arnason BGW. Relevance of EAE to multiple sclerosis. Neural Clin 1983; 1: 765-81.